{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:32:31Z","timestamp":1784215951137,"version":"3.55.0"},"reference-count":54,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2017-I2M-3-022"],"award-info":[{"award-number":["2017-I2M-3-022"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Science and Technology Special Projects of Yunnan Province","award":["202002AA100009"],"award-info":[{"award-number":["202002AA100009"]}]},{"name":"Basic Research Projects of Yunnan Province","award":["Unassigned"],"award-info":[{"award-number":["Unassigned"]}]},{"name":"Funds for the Training of High-level Health Technical Personnel in Yunnan Province","award":["H-2019063"],"award-info":[{"award-number":["H-2019063"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Theoretically, the subunit herpes zoster vaccine ShingrixTM could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated with varicella-zoster virus glycoprotein E (VZV-gE) and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and the natural phosphodiester CpG oligodeoxynucleotide (CpG ODN), which was approved by the FDA as an immunostimulator in a hepatitis B vaccine. Preclinical trial in mice showed that these LNP vaccines could induce VZV-gE IgG titers more than 16 times those induced by an alum adjuvant, and immunized serum could block in vitro infection completely at a dilution of 1:80, which indicated potential as a varicella vaccine. The magnitude of the cell-mediated immunity induced was generally more than 10 times that induced by the alum adjuvant, indicating potential as a zoster vaccine. These results showed that immunostimulatory nucleic acids together with LNPs have promise as safe and economical varicella and zoster vaccine candidates.<\/jats:p>","DOI":"10.3390\/vaccines9040310","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T02:54:03Z","timestamp":1616640843000},"page":"310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice"],"prefix":"10.3390","volume":"9","author":[{"given":"Han","family":"Cao","sequence":"first","affiliation":[{"name":"Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-7464","authenticated-orcid":false,"given":"Ning","family":"Luan","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-2612","authenticated-orcid":false,"given":"Cunbao","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13365-017-0519-y","article-title":"Incidence of varicella zoster virus infections of the central nervous system in the elderly: A large tertiary hospital-based series (2007\u20132014)","volume":"23","author":"Arruti","year":"2017","journal-title":"J. Neurovirol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiy279","article-title":"Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain, and the Pathogenesis of Latency and Reactivation","volume":"218","author":"Breuer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0950268800050019","article-title":"The epidemiology of varicella-zoster virus infections: The influence of varicella on the prevalence of herpes zoster","volume":"108","author":"Garnett","year":"1992","journal-title":"Epidemiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/74715","article-title":"Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children","volume":"6","author":"Krause","year":"2000","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14760584.2017.1395703","article-title":"Studies with herpes zoster vaccines in immune compromised patients","volume":"16","author":"Levin","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moodley, A., Swanson, J., Grose, C., and Bonthius, D.J. (2019). Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children. J. Child Neurol.","DOI":"10.1177\/0883073818821498"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00431-002-0981-1","article-title":"Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child","volume":"161","author":"Uebe","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Haberthur, K., Engelmann, F., Park, B., Barron, A., Legasse, A., Dewane, J., Fischer, M., Kerns, A., Brown, M., and Messaoudi, I. (2011). CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002367"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/JVI.03445-13","article-title":"Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia","volume":"88","author":"Steain","year":"2014","journal-title":"J. Virol."},{"key":"ref_14","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMe1505050","article-title":"A new vaccine to prevent herpes zoster","volume":"372","author":"Cohen","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Clement","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/21645515.2017.1420446","article-title":"Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model","volume":"14","author":"Liu","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijpharm.2018.10.054","article-title":"Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors","volume":"553","author":"Liu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijpharm.2015.10.057","article-title":"Double emulsion solvent evaporation techniques used for drug encapsulation","volume":"496","author":"Iqbal","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, Y., Qi, J., Cao, H., and Liu, C. (2020). Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice. Virol. Sin.","DOI":"10.1007\/s12250-020-00261-y"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1021\/acsnano.7b04734","article-title":"Next-Generation Lipids in RNA Interference Therapeutics","volume":"11","author":"Rietwyk","year":"2017","journal-title":"ACS Nano"},{"key":"ref_30","first-page":"709","article-title":"mRNA-Based Therapeutics\u2014Advances and Perspectives","volume":"81","author":"Sergeeva","year":"2016","journal-title":"Biochemistry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.vaccine.2020.12.005","article-title":"Effects of rotavirus NSP4 protein on the immune response and protection of the SR69A-VP8* nanoparticle rotavirus vaccine","volume":"39","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jmv.26320","article-title":"SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1128\/IAI.71.12.6915-6920.2003","article-title":"Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3","volume":"71","author":"Lefeber","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-3024.1994.tb00306.x","article-title":"The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni","volume":"16","author":"Mountford","year":"1994","journal-title":"Parasite Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.00533-06","article-title":"Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection","volume":"80","author":"Berarducci","year":"2006","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1128\/JVI.78.22.12406-12415.2004","article-title":"Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo","volume":"78","author":"Moffat","year":"2004","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0264-410X(96)00228-9","article-title":"Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE)","volume":"15","author":"Fowler","year":"1997","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.vaccine.2016.02.007","article-title":"A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice","volume":"34","author":"Zhu","year":"2016","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00425-018-2911-0","article-title":"Recent advances in steroidal saponins biosynthesis and in vitro production","volume":"248","author":"Upadhyay","year":"2018","journal-title":"Planta"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/JVI.03124-14","article-title":"Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge","volume":"89","author":"Meyer","year":"2015","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mpat.1993.1064","article-title":"A mouse model for varicella-zoster virus latency","volume":"15","author":"Wroblewska","year":"1993","journal-title":"Microb. Pathog."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z","article-title":"CpG-DNA aided cross-presentation of soluble antigens by dendritic cells","volume":"32","author":"Maurer","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.vaccine.2017.10.097","article-title":"A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen","volume":"35","author":"Kalimuddin","year":"2017","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370 years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: Examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int. J. Nanomed."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:40:44Z","timestamp":1760161244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["vaccines9040310"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9040310","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}